A review of new science, in plain language

Science Advances  ·  11 September 2026  ·  From issue 36

Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1

In mice, blocking a protein called SPP1 made immune therapy shrink KRAS-mutant lung tumors better.

Xin Zhang, Qian Hao et al.

Lung cancers with two specific gene changes, one in a gene called KRAS and one in a gene called TP53, respond better to immune therapy. The reason is a protein called SPP1. When both genes are mutated, SPP1 drops. Lower SPP1 lets more cancer-fighting immune cells enter the tumor and blocks fewer cells that would shut those fighters down.

Integrity screen: passed (3 checks) Checked 16 September 2026. Read the source

The plain-language reading of this paper is in the full issue, for subscribers.

Read the full issue

Five vetted papers in plain language, free, every two days

Five papers free every issue, about 15 emails a month. No spam. Leave in one click.

Also in issue 36 15 papers
More from Science Advances